Monopar Therapeutics Inc. Deferred Offering Costs
Monopar Therapeutics Inc. (MNPR) had Deferred Offering Costs of $10.34 thousand as of 2019-12-31, per its 10-K filed 2020-03-27.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2020-03-27
- 2019-12-31: Deferred Offering Costs $10.34K.
- 2019-09-30: Deferred Offering Costs $529.20K.
- 2019-06-30: Deferred Offering Costs $371.11K.
- 2019-03-31: Deferred Offering Costs $371.11K.
| Period end | Deferred Offering Costs |
|---|---|
| 2019-12-31 | $10.34K 10-K · filed 2020-03-27 |
| 2019-09-30 | $529.20K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $371.11K 10-Q · filed 2019-08-08 |
| 2019-03-31 | $371.11K 10-Q · filed 2019-05-10 |
| 2018-12-31 | $344.94K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |